Owens & Minor Inc Is Suddenly On Everyone’s Radar – But Is The Hype Even Real?
Owens & Minor Inc (OMI) is gaining attention as a "boring but crucial" healthcare infrastructure stock, specializing in medical supplies and logistics. While not a flashy stock, it's attracting investors interested in recession-resistant healthcare supply chains due to the constant demand for medical products. However, investors are cautioned to consider its volatility, debt levels, and the need for management to deliver on cost-cutting and margin improvements due to its history of price swings.
Owens & Minor Inc Is Suddenly On Everyone’s Radar – But Is The Hype Even Real?
The article discusses Owens & Minor Inc (OMI), a medical supply and logistics company, and questions whether the recent buzz around it is warranted. It highlights OMI as a "boring but crucial" healthcare infrastructure play, attracting attention from investors interested in recession-resistant stocks and the healthcare supply chain. The piece analyzes OMI's stock performance, business model, and risk level, comparing it to larger competitors, ultimately suggesting it's a higher-risk, potentially undervalued opportunity for informed investors rather than a quick win.
Owens & Minor launches senior secured notes offering
Owens & Minor has announced an offering of senior secured notes. Proceeds from this offering are expected to be used for general corporate purposes, which may include debt repayment or funding future growth initiatives for the company.
Owens & Minor’s Stock Tests Investors’ Patience As Wall Street Waits For A Turnaround
Owens & Minor's (OMI) stock has been underperforming, trading near its 52-week low, reflecting market skepticism despite the company's multi-year transformation efforts. The stock has experienced a double-digit decline over the past 90 days, testing existing shareholders' patience. Wall Street analysts maintain a cautiously neutral to pessimistic stance, with most recommendations being "Hold" and target prices indicating limited short-term upside, as the market awaits tangible proof of improved margins and deleveraging.
Owens & Minor changes name to Accendra Health
Owens & Minor, a company previously known for its distribution and manufacturing services for the healthcare industry, has officially changed its corporate name to Accendra Health. This rebranding signifies a strategic shift or renewed focus for the organization.
Owens & Minor, Inc. (OMI): Investor Outlook Reveals 94% Potential Upside Amidst Challenging Valuation
Owens & Minor, Inc. (OMI), a key player in the U.S. healthcare distribution industry, is facing financial challenges despite a potential 94.29% upside indicated by an average analyst target price of $5.44. The company, recently rebranded as Accendra Health, Inc., is grappling with profitability issues, as evidenced by a negative EPS and return on equity, and slow revenue growth. While technical indicators suggest the stock is oversold, investor sentiment is mixed, highlighting the uncertainty surrounding its turnaround efforts.
Owens & Minor rebrands as Accendra Health in transformation
Owens & Minor, a healthcare solutions company, has rebranded itself as Accendra Health. This transformation signifies a comprehensive shift in the company's identity and strategic direction. The new name aims to better reflect its evolving role in the healthcare sector.
Owens & Minor Inc Is Suddenly On Everyone’s Radar – But Is The Hype Even Real?
Owens & Minor Inc (OMI), a healthcare supply and logistics company, is currently gaining attention from traders due to its volatility and comeback story. While it operates in a crucial, albeit unglamorous, sector, its stock has seen significant price drops in the past, leading to both "value hunter" and "trap" narratives. The article suggests OMI is a high-risk, high-reward play best suited for investors comfortable with significant volatility and who believe in its turnaround potential, rather than a stable portfolio foundation.
It’s official: Accendra Health goes live on NYSE, unveils new website
Accendra Health has begun trading on the New York Stock Exchange under the ticker symbol ACH and launched a new website, www.accendrahealth.com. This move follows the sale of its former Products & Healthcare Services business and a rebranding from Owens & Minor to better reflect its focus on the home-based care market, while still operating under the Apria and Byram Healthcare brands. Two executives departed in connection with the sale of the Products & Healthcare Services business.
Owens & Minor Completes Sale of Products & Healthcare Services Business to Platinum Equity
Owens & Minor, Inc. has sold its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity for $375 million in cash, with a 5% retained equity stake. The company is renaming itself Accendra Health, Inc., shifting its focus to a pure-play home-based care platform with its Apria and Byram brands to drive long-term value. This strategic move aims to create a more focused organization dedicated to supporting patients with chronic conditions through home-based care.
Platinum Equity Completes Acquisition Of Owens & Minor Products & Healthcare Services Business
Platinum Equity has completed its acquisition of Owens & Minor's Products & Healthcare Services unit, forming a new standalone company under the Owens & Minor brand. The acquired business will continue to provide medical and surgical supply distribution primarily to the acute care market in the U.S. Owens & Minor, the seller, retains a five percent interest and will rebrand its remaining operations as Accendra Health, Inc.
Owens & Minor (OMI) Options to be Delisted in Early January
Owens & Minor (OMI) will have its options delisted on January 2nd, 2026, which could impact trading strategies and liquidity for investors. The healthcare logistics firm, with a market cap of $216.57 million, faces financial challenges including negative earnings growth, a low Piotroski F-Score, and concerning liquidity ratios. Investors should consider these factors and the stock's high volatility when evaluating investment opportunities.
Owens & Minor, Inc. (NYSE:OMI) Given Consensus Recommendation of "Hold" by Analysts
Analysts have issued a consensus "Hold" rating for Owens & Minor, Inc. (NYSE:OMI), with an average one-year target price of $6.35. The stock is trading near its 52-week low with a market capitalization of $212 million and a high debt-to-equity ratio, despite beating EPS estimates in its last quarter. Institutional investors hold a significant 98% stake in the company.
Owens & Minor, Inc. Completes Sale of Products & Healthcare Services Business to Platinum Equity
Owens & Minor, Inc. has announced the completion of the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity. The company will now be renamed Accendra Health, Inc., signifying its transformation into a pure-play leader in the home-based care market. This strategic move aims to create a more focused organization, dedicated to supporting patients with chronic conditions through home-based care.
Owens & Minor (NYSE: OMI) closes $375M P&HS sale and adopts Accendra Health name
Owens & Minor completed the sale of its Products & Healthcare Services (P&HS) business for $375 million and concurrently adopted the name Accendra Health, Inc., effective December 31, 2025. The company also amended its receivables sale program and experienced executive changes in connection with the divestiture. Trading under the new name and ticker "ACH" on the NYSE is expected to commence on January 2, 2026.
Owens & Minor Announces Executive Management Changes
Owens & Minor, Inc. has announced significant executive management changes effective on the Closing Date. Andrew G. Long and Michael W. Lowry have departed from their roles, while Jonathan A. Leon has taken on additional responsibilities as Executive Vice President & Chief Financial Officer. These changes are in connection with recent transactions.
Platinum Equity Completes Acquisition of Owens & Minor Products & Healthcare Services Business
Platinum Equity has completed its acquisition of Owens & Minor Products & Healthcare Services (Owens & Minor P&HS), which will now operate as a standalone, privately held company under Platinum's portfolio. The acquired business will retain the Owens & Minor brand, while the seller's retained business will be rebranded as Accendra Health, Inc. Platinum Equity plans to leverage its expertise to strengthen the company's foundation, expand capabilities, and enhance operational excellence and growth.
Owens & Minor completes sale of products segment, rebrands as Accendra
Owens & Minor, Inc. (NYSE:OMI) has finalized the sale of its Products & Healthcare Services segment and the Owens & Minor brand to Platinum Equity for $375 million in cash. The company, now rebranded as Accendra Health, Inc., will focus on the home-based care market through its Apria and Byram brands, aiming to address its debt and liquidity challenges. This strategic move follows a period of cash burn and has led to a downgrade in its Corporate Family Rating by Moody's and a downgrade from UBS.
Owens & Minor to change name on Dec. 31
Owens & Minor, a Fortune 500 healthcare logistics company, will change its corporate name to Accendra Health on December 31, 2025, to better reflect its focus on the home-based care market. This rebranding will also include a new stock ticker symbol "ACH" on the NYSE starting January 2, 2026. The move follows the sale of its largest business segment and the termination of a major acquisition, as the company sharpens its strategic direction.
Owens & Minor to rebrand as Accendra Health, change ticker to ACH
Owens & Minor, Inc. (NYSE:OMI) announced it will change its corporate name to Accendra Health, Inc. effective December 31, 2025, and will trade under the new ticker symbol "ACH" on the NYSE starting January 2, 2026. This rebranding signifies its strategic transformation into a focused home-based care business, despite currently carrying a significant debt burden, with analysts expecting a return to profitability this year. The name change applies only to the parent corporation, while its Apria and Byram Healthcare brands will continue operating under their current names.
Owens & Minor to rebrand to ‘Accendra Health’
Owens & Minor (NYSE:OMI) announced its rebranding to "Accendra Health," effective December 31, 2025, to reflect its new focus as a pure-play home-based care business. This change follows the sale of its Products & Healthcare Services segment and aims to better demonstrate its strategic direction in the home-based care market. Shares will begin trading under the new ticker "ACH" on January 2, 2026.
Owens & Minor to kick off new year with new name: Accendra Health
Owens & Minor, Inc. is set to change its name to Accendra Health, Inc. on December 31, 2025, to better reflect its focus as a leader in the home-based care market. The company will continue to operate under its Apria and Byram Healthcare brands, with its common stock trading under the new ticker symbol ACH on the NYSE starting January 2, 2026. This rebranding follows the sale of its Products & Healthcare Services segment, transforming it into a pure-play home-based care platform.
Owens & Minor Announces Corporate Name Change to Accendra Health, Inc.
Owens & Minor, Inc. (NYSE: OMI) announced its corporate name will change to Accendra Health, Inc., effective December 31, 2025, to better reflect its focus on home-based care. The company will trade under the new ticker symbol "ACH" on the NYSE starting January 2, 2026, and launch a new website. The change only affects the parent corporation's name, with Apria and Byram Healthcare brands continuing to operate under their existing names.
Moody’s downgrades Owens & Minor to B2 amid business segment sale
Moody's Ratings has downgraded Owens & Minor, Inc.'s Corporate Family Rating (CFR) to B2 from Ba3, changing the outlook to negative, due to the planned sale of its Products & Healthcare Services (P&HS) segment. The downgrade reflects reduced scale and diversification, with limited deleveraging expected as net proceeds are small compared to total debt. Post-sale, Owens & Minor will operate solely through its Patient Direct segment, increasing concentration risk and exposure to reimbursement challenges, while maintaining good liquidity is anticipated.
Moody’s downgrades Owens & Minor to B2 amid business segment sale
Moody’s Ratings has downgraded Owens & Minor’s Corporate Family Rating to B2 from Ba3, alongside other ratings, and changed its outlook to negative. This downgrade follows the planned sale of the company's Products & Healthcare Services segment, which reduces its scale and diversification. The negative outlook also reflects potential separation costs and uncertainty regarding the growth of the standalone Patient Direct business, which will be the company's sole segment after the sale.
Owens & Minor appoints Perry A. Bernocchi as chief operating officer
Owens & Minor, Inc. (NYSE:OMI) has appointed Perry A. Bernocchi as executive vice president and chief operating officer, effective immediately. Bernocchi, previously EVP and CEO of the Patient Direct segment, will retain his compensation and employment terms. The company also announced that Jennifer Stone, EVP and chief human resources officer, will depart on December 31, 2025, with Heath Galloway assuming oversight of human resources.
Owens & Minor names new COO as CHRO departs
Owens & Minor (NYSE: OMI) has appointed Perry A. Bernocchi as EVP and chief operating officer, effective Dec. 5, 2025. Bernocchi previously led the company's Patient Direct segment. Concurrently, Jennifer Stone, EVP and chief human resources officer, will depart on Dec. 31, 2025, and the CHRO position will be eliminated, with Heath Galloway taking over HR oversight.
Owens & Minor, Inc. (NYSE:OMI) Given Average Recommendation of "Hold" by Brokerages
Owens & Minor, Inc. (NYSE:OMI) has received a consensus "Hold" rating from eight analysts, with an average one-year price target of $6.35. The stock is currently trading near its 52-week low and exhibits high leverage. Despite beating EPS estimates slightly in its latest earnings report, the company's revenue was marginally below expectations, but institutional ownership remains high at 98.04% after significant stake increases.
Do Options Traders Know Something About Owens & Minor Stock We Don't?
Options traders are showing high implied volatility for Owens & Minor (OMI) stock, specifically for the Dec 19, 2025 $25.00 Call, suggesting expectations of a significant price movement. Despite this, the company currently holds a Zacks Rank #5 (Strong Sell) in the Medical-Products Industry, with analysts having recently revised estimates downwards. This high implied volatility, coupled with a bearish fundamental picture, might indicate an opportunity for seasoned options traders to sell premium.
Owens & Minor Inc Announces Participation in Investor Conferences
Owens & Minor Inc. announced that its CEO, Ed Pesicka, will speak at the Citi 2025 Global Healthcare Conference, and its CFO, Jon Leon, will attend the Bank of America Leveraged Finance Conference. The company aims to focus on strategic priorities, capital allocation after the P&HS sale, and improve cash flow and debt repayment, anticipating long-term growth from home-based care market trends.
Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025
Owens & Minor, Inc. (NYSE: OMI) announced that members of its management team will participate in two upcoming investor conferences on December 2, 2025. Ed Pesicka and Will Parrish will present at the Citi 2025 Global Healthcare Conference, while Jon Leon and Alex Miller will host meetings at the Bank of America Leveraged Finance Conference. The company invites interested parties to attend a live webcast of the Citi conference presentation or access a replay afterwards.
Owens & Minor to Present at Upcoming Investor Conferences on December 2, 2025
Owens & Minor, Inc. announced that members of its management team will participate in two investor conferences on December 2, 2025. Ed Pesicka and Will Parrish will attend the Citi 2025 Global Healthcare Conference, while Jon Leon and Alex Miller will be at the Bank of America Leveraged Finance Conference, both hosting one-on-one investor meetings.
Owens & Minor, Inc. Stock (OMI) Opinions on Strategic Shift to Patient Direct
Discussions on social media platform X reveal mixed opinions on Owens & Minor, Inc.'s strategic shift to focus entirely on its Patient Direct business after divesting its legacy healthcare services segment. While some users are optimistic about its partnership with Optum Health for home-based care, others are concerned about financial risks due to accelerating losses and high leverage. The company's stock is viewed as a high-risk play, with skeptics questioning its recovery amidst forecasted revenue declines.
Owens & Minor rebrands to sharpen focus on home-based care
Owens & Minor is rebranding to align its strategic focus solely on its Patient Direct business, following the divestiture of its Products & Healthcare Services segment. This strategic shift aims to unify capital allocation and execution towards advancing home-based care. The company is also leveraging a new national provider agreement with Optum Health to drive growth in Patient Direct, alongside efforts to manage debt and operational costs.
Owens & Minor Inc (OMI) Q3 2025 Earnings Call Highlights: Strategic Divestiture and Revenue ...
Owens & Minor Inc (OMI) reported Q3 2025 revenue of $697 million and adjusted EBITDA of $92 million, along with full-year guidance for revenue and net income. The company announced the divestiture of its Products & Healthcare Services segment to Platinum Equity, retaining an equity interest, and is focusing on its higher-margin Patient Direct business. Despite a decrease in adjusted EBITDA for Q3 2025 and facing a large customer loss in 2026, the company expects strong performance in 2026, aiming for decent top-line growth and margin improvement while staying compliant with covenants.
Dimensional Fund Advisors LP Reduces Stake in Owens & Minor Inc - GuruFocus
Dimensional Fund Advisors LP reduced its stake in Owens & Minor Inc by 17.63%, selling 750,606 shares. Despite the reduction, the firm still holds over 3.5 million shares, representing 4.50% of its portfolio. This transaction highlights challenges for Owens & Minor Inc in the medical distribution sector, with the stock price declining post-transaction and showing poor GF Value and performance metrics.
Owens & Minor Announces Date and Time Change of Third Quarter 2025 Financial Results and Conference Call - The AI Journal
Owens & Minor, Inc. (NYSE: OMI) has announced a date and time change for the release of its third-quarter 2025 financial results. The company will now release its results on Thursday, October 30, 2025, after market close, and will host a conference call for investors and analysts at 5:00 p.m. EDT on the same day.
Owens & Minor, Inc. Hits New 52-Week Low at $4.35 - Markets Mojo
Owens & Minor, Inc. recently hit a new 52-week low of $4.35 on October 10, 2025, reflecting a significant 73.66% stock price decline over the past year. The company's financial metrics show a low P/E ratio of 6.00 and concerning indicators such as a negative Return on Equity of -76.43% and a high Debt to Equity ratio of -7.06, indicating valuation and profitability challenges. Despite a 20.30% compound annual growth rate in operating profits over five years, the company struggles with overall profitability as evidenced by a low Return on Capital Employed of 11.05%.
Business in brief: Oct. 13, 2025 - Henrico Citizen
This "Business in brief" update features several key developments in the Henrico area. Dr. Marcel Lambrechts of Seven Pines Dental has been named president-elect of the Virginia Dental Association. Bon Secours St. Mary's Hospital is undertaking a significant $370 million expansion, and Owens & Minor has sold its Products and Healthcare Services segment for $375 million to Platinum Equity, shifting its focus to home-based care.
Owens & Minor to sell largest business segment for $375M
Owens & Minor, a Fortune 500 company based in Henrico County, announced its plan to sell its Products & Healthcare Services segment for $375 million to Platinum Equity. This divestment will allow Owens & Minor to focus on its more profitable Patient Direct service, which provides home medical equipment. The sale, expected to close late this year, means the company will significantly shrink and likely cease to be on the Fortune 500 list, following a prior decision to back out of a $1.36 billion acquisition of Rotech Healthcare Holdings.
Owens & Minor sells Products & Healthcare Services segment to Platinum Equity for $375M
Owens & Minor has signed a definitive agreement to sell its Products & Healthcare Services (P&HS) segment to Platinum Equity for $375 million in cash. This divestiture supports Owens & Minor’s transformation into a pure-play home-based care platform, centered around its Patient Direct business, and the company plans to use the net proceeds to reduce its outstanding debt. Platinum Equity, a global investment firm, expressed confidence in the future of the P&HS business as a standalone company.
Platinum Equity to Acquire Products & Healthcare Services Business from Owens & Minor
Platinum Equity has announced a definitive agreement to acquire the Products & Healthcare Services (P&HS) segment from Owens & Minor (NYSE: OMI). Owens & Minor will retain a 5% equity stake in the Richmond, VA-based business, which is a key distributor of medical and surgical supplies primarily to the acute care market. Platinum Equity plans to leverage its operational expertise to enhance P&HS's capabilities and capitalize on the long-term demand for medical supplies driven by an aging U.S. population and increasing healthcare needs.
Owens & Minor Breaks Ground on West Virginia Facility
Owens & Minor has broken ground on a new 350,000 square-foot medical distribution facility in Morgantown, West Virginia, expected to be completed in late 2023. This facility, representing an estimated $50 million investment, is part of a partnership with West Virginia University Health System and will bring over 100 jobs to the state. It will provide clinical supply capabilities for surgical kitting, custom procedure tray assembly, and sterilization, enhancing the region's healthcare resilience.
Owens & Minor Completes $1.6B Acquisition of Apria
Owens & Minor Inc. has finalized its $1.6 billion acquisition of Apria Inc., integrating Apria with Owens & Minor's Byram Healthcare business to establish a new Patient Direct segment. This strategic move aims to expand Owens & Minor's presence in the growing home health industry and enhance its ability to provide healthcare beyond traditional hospital settings. Daniel Starck, former Apria CEO, will lead the new Patient Direct segment, which will combine Byram and Apria, while Products & Healthcare Services will encompass global products, medical distribution, and services businesses.
Owens & Minor, Inc. Completes Acquisition of Apria, Inc.
Owens & Minor, Inc. announced the completion of its acquisition of Apria, Inc. for approximately $1.6 billion. This acquisition combines Apria with Owens & Minor’s existing Byram Healthcare business, forming a new Patient Direct segment to expand its presence in the home healthcare market. The move is expected to enhance patient services by offering a broader portfolio of products for chronic and non-chronic conditions.
Owens & Minor Finalizes Apria Acquisition
Owens & Minor Inc. has completed its acquisition of Apria Inc. for approximately $1.6 billion, marking its largest acquisition to date. This move strengthens Owens & Minor's position in the home health industry by combining Apria with its existing Byram Healthcare business to form a new Patient Direct segment. The acquisition expands Owens & Minor's home healthcare product and service portfolio and geographic reach.
Medical logistics/distribution center to open in Morgantown
WVU Medicine and Owens & Minor are partnering to open a new medical logistics and distribution center in Morgantown, West Virginia. This project will create 125 jobs and expand the WVU Health System's infrastructure.
Owens & Minor, Inc. Signs Definitive Agreement to Acquire Apria, Inc.
Owens & Minor, Inc. announced its definitive agreement to acquire Apria, Inc. for approximately $1.45 billion in cash, or $37.50 per share. This acquisition aims to strengthen Owens & Minor's presence in the higher-growth home healthcare market, expand its Patient Direct platform, and create a leading platform for future growth by combining complementary product portfolios. The transaction is expected to close in the first half of 2022, subject to regulatory and stockholder approvals.
Owens & Minor to buy home healthcare provider Apria for $1.45 bln
Owens & Minor Inc. announced its acquisition of home healthcare provider Apria Inc. for approximately $1.45 billion in cash. This strategic move aims to strengthen Owens & Minor's position in the growing home healthcare services market, reflecting increased demand due to the ongoing COVID-19 pandemic. The deal, valued at $37.50 per share for Apria, is expected to close in the first half of 2022.
Apria to be Acquired in $1.6B Deal
Owens & Minor Inc. (NYSE: OMI) has announced its intention to acquire Apria Inc. (Nasdaq: APR) in a deal valued at $1.6 billion. The acquisition, expected to close in the first half of 2022, will position Owens & Minor as a leader in the home healthcare market by combining Apria's respiratory, sleep apnea, and wound therapy specialties with Owens & Minor's Byram Healthcare subsidiary. This move also diversifies Owens & Minor's revenue stream into the higher-growth home healthcare sector.
